Skip to content

Drug interactions

Eliglustat + Sofosbuvir-velpatasvir-voxilaprevir

Severity: Moderate

Eliglustat and Sofosbuvir-velpatasvir-voxilaprevir: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Eliglustat inhibits P-gp, and sofosbuvir, velpatasvir and voxilaprevir are P-gp substrates. Exposure to the HCV drugs may increase. The clinical impact is likely small given their safety margin.

What this interaction means in plain words

Eliglustat and Sofosbuvir-velpatasvir-voxilaprevir can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Eliglustat belongs to Miscellaneous; Sofosbuvir-velpatasvir-voxilaprevir belongs to Anti Virals.

Evidence level: Low

Why it happens

Eliglustat inhibits P-gp efflux, which increases absorption of the HCV drugs.

What to do

Monitor for HCV regimen adverse effects. No empiric dose change is established for the HCV drugs.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Eliglustat and Sofosbuvir-velpatasvir-voxilaprevir, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Eliglustat with Sofosbuvir-velpatasvir-voxilaprevir?

MediHelp rates the interaction as moderate. Eliglustat and Sofosbuvir-velpatasvir-voxilaprevir can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Eliglustat inhibits P-gp, and sofosbuvir, velpatasvir and voxilaprevir are P-gp substrates. Exposure to the HCV drugs may increase. The clinical impact is likely small given their safety margin.

How serious is the interaction between Eliglustat and Sofosbuvir-velpatasvir-voxilaprevir?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for HCV regimen adverse effects. No empiric dose change is established for the HCV drugs.

What other medicines interact with Sofosbuvir-velpatasvir-voxilaprevir?

MediHelp also lists interactions of Sofosbuvir-velpatasvir-voxilaprevir with, for example, Fosphenytoin, Phenobarbital, Phenytoin. The full list is on the Sofosbuvir-velpatasvir-voxilaprevir page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in